Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Icahn School of Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Brains Bioceutical Initiates Clinical Trial Agreement To Tackle Opioid Addiction
Details : As part of this study initiation, the Icahn School of Medicine at Mount Sinai in New York, NY, is initiating the PK study with Brains Bio’s oral drug formulation of Cannabidiol (CBD) in a hard gelatin capsule.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 09, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Icahn School of Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
